Edgewise Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Edgewise Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2020 to 2023.
  • Edgewise Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $241M.
  • Edgewise Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $53.2M, a 59% decline from 2022.
  • Edgewise Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $130M, a 30.4% decline from 2021.
  • Edgewise Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $186M, a 55% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $53.2M -$76.5M -59% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 $130M -$56.7M -30.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 $186M +$66.1M +55% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-23
2020 $120M Jan 1, 2020 Dec 31, 2020 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.